Cargando…

Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature

PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Meng, Chen, Huihui, Deng, Hao, Jin, Yao, Wang, Gui, Zhang, Kun, Ma, Hong, Chen, Yiding, Zhang, Suzhan, Zhou, Jiaojiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152099/
https://www.ncbi.nlm.nih.gov/pubmed/35656513
http://dx.doi.org/10.3389/fonc.2022.881047
Descripción
Sumario:PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after NAC with or without PMRT, and to discuss the selection of patients who may omit PMRT. PATIENTS AND METHODS: From January 2005 to December 2017, 3055 female breast cancer patients underwent mastectomy in our medical center, among whom 215 patients of cT(1-2)N(+) stage, receiving NAC with or without PMRT were finally analyzed. The median follow-up duration was 72.6 months. The primary endpoint was disease-free survival (DFS), and secondary endpoint was overall survival (OS). Comparison was conducted between PMRT and non-PMRT subgroups. RESULTS: Of the 215 eligible patients, 35.8% (77/215) cT(1-2)N(+) patients achieved ypT(0-2)N(0) after NAC while 64.2% (138/215) of the patients remained nodal positive (ypT(0-2)N(+)). The 5-year DFS of ypT(0-2)N(0) non-PMRT was 79.5% (95% confidence interval [CI] 63.4-95.6%). No statistically significant difference was observed between the ypT(0-2)N(0) PMRT and non-PMRT subgroups for the 5-year DFS (78.5% vs 79.5%, p = 0.673) and OS (88.8% vs 90.8%, p = 0.721). The 5-years DFS didn’t obviously differ between the ypT(0-2)N(0) non-PMRT subgroup and cT(1-2)N(0) subgroup (79.5% vs 93.3%, p = 0.070). By using Cox regression model in multivariate analyses of prognosis in ypT(0-2)N(+) PMRT subgroup, HER2 overexpression and triple-negative breast cancer were significantly poor predictors of DFS and OS, while ypN stage was significant independent predictors of OS. CONCLUSION: An effective response to NAC (ypT(0-2)N(0)) indicates a sufficiently favorable prognosis, and PMRT might be omitted for cT(1-2)N(+) breast cancer patients with ypT(0-2)N(0) after NAC.